Holen Sie sich die Stockscreener-App
24.21
3.46%
0.81
Handel nachbörslich:
23.95
-0.26
-1.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
New Ultragenyx hires get 16,355 stock units vesting over 4 years - Stock Titan
Ultragenyx Pharmaceutical Inc. Faces Setback as Phase III Studies Fail to Meet Primary Endpoint - Intellectia AI
Bone drug lifts density but not fractures, drawing Ultragenyx investor scrutiny - Stock Titan
Emerald Mutual Fund Advisers Trust Sells 52,515 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical's Phase III Study Fails to Meet Primary Endpoint, Analysts Cut Price Targets - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline - Seeking Alpha
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring the 184% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Campbell & CO Investment Adviser LLC Grows Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Lobbying Update: $60,000 of ULTRAGENYX PHARMACEUTICAL INC. lobbying was just disclosed - Quiver Quantitative
2026-01-16 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Shareholders to Reach Out | NDAQ:RARE | Press Release - Stockhouse
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
Cantor Fitzgerald maintains $118 target on Ultragenyx stock - MSN
Dividend Watch: What are the future prospects of Ultragenyx Pharmaceutical Inc2025 Earnings Impact & Growth Focused Investment Plans - baoquankhu1.vn
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Upgraded 2025 Guidance And DTX401 BLA Completion - Sahm
Will Ultragenyx Pharmaceutical Inc outperform tech stocksStop Loss & Consistent Income Trade Recommendations - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Quarterly Recap: Is Ultragenyx Pharmaceutical Inc stock ready for breakoutTrend Reversal & Daily Chart Pattern Signals - Bộ Nội Vụ
Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 39.1% One Year Decline? - Yahoo Finance
Ultragenyx reports preliminary 2025 revenue of $672-674 million By Investing.com - Investing.com Nigeria
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Revenue Beat And Gene Therapy Catalysts Update - Yahoo Finance
Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery - Insider Monkey
Ultragenyx reports preliminary 2025 revenue of $672-674 million - Investing.com
Ultragenyx Pharmaceutical Inc. Reports Preliminary 2025 Revenue of $672 Million to $674 Million, Exceeding Guidance - Quiver Quantitative
Ultragenyx provides financial and business updates at J.P. Morgan Annual Healthcare Conference - marketscreener.com
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference - The Manila Times
SG Americas Securities LLC Purchases Shares of 125,429 Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Analysts lower Ultragenyx (RARE) target but stay bullish - MSN
2026-01-11 | Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation | NDAQ:RARE | Press Release - Stockhouse
Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission - MSN
Ultragenyx (RARE) Earnings Call Highlights Growth and Challenges - MSN
Can Ultragenyx Pharmaceutical Inc. (UP0) stock beat analyst consensusEntry Point & Reliable Price Breakout Alerts - Улправда
Why Ultragenyx Pharmaceutical Inc. stock is trending among retail tradersPrice Action & Low Risk Entry Point Guides - ulpravda.ru
Can Ultragenyx Pharmaceutical Inc. stock rebound after recent weaknessMarket Movers & Fast Momentum Entry Tips - ulpravda.ru
Analysts Lower Ultragenyx (RARE) Target but Stay Bullish - Insider Monkey
Looking Into Ultragenyx Pharmaceutical Inc's Recent Short Interest - Sahm
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
RARE ALERT: Ongoing Investigation Into Ultragenyx Pharmaceutical Inc.Contact Levi & Korsinsky - ACCESS Newswire
Ongoing Investigation into Ultragenyx Pharmaceutical Inc. (RARE): Contact Levi & Korsinsky About Potential Fraud - ACCESS Newswire
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
How Ultragenyx Pharmaceutical Inc. stock valuations compare to rivals2025 Volatility Report & Safe Entry Trade Reports - ulpravda.ru
2026-01-08 | Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:RARE | Press Release - Stockhouse
Is Ultragenyx Pharmaceutical Inc. (UP0) stock a buy before earnings results2025 Dividend Review & AI Based Trade Execution Alerts - ulpravda.ru
Looking at the Latest Short Interest Activity for Ultragenyx Pharmaceutical Inc - Bitget
RBC Cuts Price Target on Ultragenyx Pharmaceutical to $35 From $72, Keeps Outperform, Speculative Risk - MarketScreener
Kyowa Kirin and Ultragenyx to proceed with US regulatory bid for burosumab - The Pharma Letter
Ultragenyx Pharmaceutical Inc. CEO to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
2.92%
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):